tirzepatide kidney (Zepbound) showed improved function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https SURPASS-CVOT: Tirzepatide Significantly Reduces Major

Supporting this with appropriate nutrition, including adequate protein to maintain gut epithelial cell turnover, represents a logical adjunct

European Journal of Pharmaceutical Sciences, 4 (3), 167174

Which of the GLP-1s are now explicitly approved for weight loss

Route of Administration Insights Why did the parenteral segment dominate the obesity GLP-1 market

Please refer to your institutions compliance protocols before use

(10) M Soyka and H B Rothenhaeusler (1998) Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial Journal of Clinical Psychopharmacology, 1998 Jun, Volume 18 (Issue 3), Pages 257-8